These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 4071633)

  • 1. Inactivated polio vaccine: industrial production from micro-carrier Vero cells culture.
    Montagnon BJ
    Trop Geogr Med; 1985 Sep; 37(3):S40-1. PubMed ID: 4071633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line.
    Montagnon BJ
    Dev Biol Stand; 1989; 70():27-47. PubMed ID: 2759353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
    Bakker WA; Thomassen YE; van't Oever AG; Westdijk J; van Oijen MG; Sundermann LC; van't Veld P; Sleeman E; van Nimwegen FW; Hamidi A; Kersten GF; van den Heuvel N; Hendriks JT; van der Pol LA
    Vaccine; 2011 Sep; 29(41):7188-96. PubMed ID: 21651934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine.
    Montagnon BJ; Fanget B; Nicolas AJ
    Dev Biol Stand; 1981; 47():55-64. PubMed ID: 6785126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production, testing and perspectives of IPV and IPV combination vaccines: GSK biologicals' view.
    Duchêne M
    Biologicals; 2006 Jun; 34(2):163-6. PubMed ID: 16682218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technology transfer of Sabin-IPV to new developing country markets.
    Kreeftenberg H; van der Velden T; Kersten G; van der Heuvel N; de Bruijn M
    Biologicals; 2006 Jun; 34(2):155-8. PubMed ID: 16650773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of inactivated poliovirus vaccine derived from Sabin strains.
    Simizu B; Abe S; Yamamoto H; Tano Y; Ota Y; Miyazawa M; Horie H; Satoh K; Wakabayashi K
    Biologicals; 2006 Jun; 34(2):151-4. PubMed ID: 16679028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thousand litre scale microcarrier culture of Vero cells for killed polio virus vaccine. Promising results.
    Montagnon B; Vincent-Falquet JC; Fanget B
    Dev Biol Stand; 1983; 55():37-42. PubMed ID: 6677539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier.
    Montagnon BJ; Fanget B; Vincent-Falquet JC
    Rev Infect Dis; 1984; 6 Suppl 2():S341-4. PubMed ID: 6740071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
    Yang C; Shi H; Zhou J; Liang Y; Xu H
    Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of sensitivity of VERO cell line versus primary monkey kidney cells in the detection of residual live polio virus during and after inactivation.
    Montagnon BJ; Nicolas AJ; Fanget B; Peyron L
    Dev Biol Stand; 1981; 47():151-5. PubMed ID: 6262146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
    Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
    Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with vero cells at Pasteur Mérieux Connaught.
    Montagnon BJ; Vincent-Falquet JC; Saluzzo JF
    Dev Biol Stand; 1999; 98():137-40; discussion 167. PubMed ID: 10494966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells.
    Haastrup E; Thierry-Carstensen B; Jensen AM; Stellfeld M; Heilmann C
    Vaccine; 2004 Feb; 22(8):958-62. PubMed ID: 15161072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developments in the production and quality control of poliovirus vaccines -- historical perspectives.
    Furesz J
    Biologicals; 2006 Jun; 34(2):87-90. PubMed ID: 16621594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proposals on the control of VERO cells used to prepare inactivated poliomyelitis vaccine.
    Ménetrat JL; Chaniot S; Lefrançois S; Canale A; Chippaux A
    Dev Biol Stand; 1981; 47():163-7. PubMed ID: 6785125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Present state and developments in the production of inactivated poliomyelitis vaccine.
    van Wezel AL
    Dev Biol Stand; 1981; 47():7-13. PubMed ID: 6262162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.
    Barrett PN; Mundt W; Kistner O; Howard MK
    Expert Rev Vaccines; 2009 May; 8(5):607-18. PubMed ID: 19397417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age.
    Pietrzyk JJ; Wysocki J; Pejcz J; Galaj A; Majda-Stanislawska E; Käyhty H; Thierry-Carstensen B; Jensen AM
    Vaccine; 2008 Sep; 26(41):5296-303. PubMed ID: 18675870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.